A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
Conditions: Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Squamous Cell Carcinoma of Head and Neck Interventions: Biological: Durvalumab; Biological: Oleclumab Sponsors: University Health Network, Toronto; AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Allergy & Immunology | AstraZeneca | Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | Lung Cancer | Molecular Biology | Non-Small Cell Lung Cancer | Pancreas | Pancreatic Cancer | Research | Skin Cancer | Squamous Cell Carcinoma | Study